BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 28679058)

  • 1. Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
    Pena A; Kobir A; Goncharov D; Goda A; Kudryashova TV; Ray A; Vanderpool R; Baust J; Chang B; Mora AL; Gorcsan J; Goncharova EA
    Am J Respir Cell Mol Biol; 2017 Nov; 57(5):615-625. PubMed ID: 28679058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.
    Goncharov DA; Kudryashova TV; Ziai H; Ihida-Stansbury K; DeLisser H; Krymskaya VP; Tuder RM; Kawut SM; Goncharova EA
    Circulation; 2014 Feb; 129(8):864-74. PubMed ID: 24270265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats.
    Zungu-Edmondson M; Shults NV; Melnyk O; Suzuki YJ
    PLoS One; 2017; 12(8):e0182551. PubMed ID: 28809956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
    Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
    Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered mTOR and Beclin-1 mediated autophagic activation during right ventricular remodeling in monocrotaline-induced pulmonary hypertension.
    Deng Y; Wu W; Guo S; Chen Y; Liu C; Gao X; Wei B
    Respir Res; 2017 Mar; 18(1):53. PubMed ID: 28340591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
    Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
    Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Leong ZP; Hikasa Y
    Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
    Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model.
    Ma X; Yao J; Yue Y; Du S; Qin H; Hou J; Wu Z
    Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):206-211. PubMed ID: 28475806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colchicine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension.
    Prins KW; Tian L; Wu D; Thenappan T; Metzger JM; Archer SL
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28566298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
    Xu EZ; Kantores C; Ivanovska J; Engelberts D; Kavanagh BP; McNamara PJ; Jankov RP
    Am J Physiol Heart Circ Physiol; 2010 Dec; 299(6):H1854-64. PubMed ID: 20889845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.
    Houssaini A; Abid S; Derumeaux G; Wan F; Parpaleix A; Rideau D; Marcos E; Kebe K; Czibik G; Sawaki D; Treins C; Dubois-Randé JL; Li Z; Amsellem V; Lipskaia L; Pende M; Adnot S
    Am J Respir Cell Mol Biol; 2016 Sep; 55(3):352-67. PubMed ID: 26991739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct right ventricle remodeling in response to pressure overload in the rat.
    Mendes-Ferreira P; Santos-Ribeiro D; Adão R; Maia-Rocha C; Mendes-Ferreira M; Sousa-Mendes C; Leite-Moreira AF; Brás-Silva C
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H85-95. PubMed ID: 27199115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension.
    Lambert M; Boet A; Rucker-Martin C; Mendes-Ferreira P; Capuano V; Hatem S; Adão R; Brás-Silva C; Hautefort A; Michel JB; Dorfmuller P; Fadel E; Kotsimbos T; Price L; Jourdon P; Montani D; Humbert M; Perros F; Antigny F
    Cardiovasc Res; 2018 May; 114(6):880-893. PubMed ID: 29360952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats.
    Nan X; Su S; Ma K; Ma X; Wang X; Zhaxi D; Ge R; Li Z; Lu D
    J Ethnopharmacol; 2018 Apr; 216():175-183. PubMed ID: 29325918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of right coronary vascular dysfunction in severe pulmonary hypertensive rats using synchrotron radiation microangiography.
    Inagaki T; Pearson JT; Tsuchimochi H; Schwenke DO; Saito S; Higuchi T; Masaki T; Umetani K; Shirai M; Nakaoka Y
    Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1021-H1036. PubMed ID: 33481696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
    Houssaini A; Abid S; Mouraret N; Wan F; Rideau D; Saker M; Marcos E; Tissot CM; Dubois-Randé JL; Amsellem V; Adnot S
    Am J Respir Cell Mol Biol; 2013 May; 48(5):568-77. PubMed ID: 23470622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.